Table 2.

Survival rates in NOD/SCID mice bearing peritoneal disseminated cells of SKOV3-luc ovarian cancer xenografts treated with DFP-10825, paclitaxel and their combination

Treatments	Doses	MSTa (days)	ILSb (%)	P-valuec
Vehicle control	Non	29.0	–	–
DFP-10825	1 mg/kgd	34.0	17.2	<0.01
Paclitaxel	15 mg/kg	62.0	113.8	<0.01#
DFP-10825 + paclitaxel	1 mg/kgd + 15 mg/kg	83.0	186.2	<0.01##

Notes: After drug treatment, survival time in mice (n=10) was monitored for 100 days after tumor implantation. Median survival time (MST) was 29 days for vehicle control, 34 days for DFP-10825 alone, 62 days for paclitaxel alone, and 83 days for combination of DFP-10825 with paclitaxel.

^aMedian survival time,

^bincrease in life span,

^csignificantly different from control group for MST,

^das shRNA dose.

^#Significantly different (P<0.01) from DFP-10825 group.

^##Significantly different (P=<0.01) from paclitaxel group.